Incyte Corporation Drug Pipeline

Incyte Corporation maintains a substantial portfolio of clinical programs, with 54 active trials out of 251 total registered trials since 2008. These active trials span multiple phases of development, including 19 in Phase 1, 18 in Phase 2, and 21 in Phase 3. The company’s research and development efforts cover seven therapeutic areas, with a significant concentration in oncology, which accounts for 61% of active programs (33 trials). Within oncology, the leading indications are advanced solid tumors (13 active trials, including 1 in Phase 3), non-Hodgkin lymphoma (4 active trials, including 3 in Phase 3), and myelofibrosis (3 active trials). Other therapeutic areas with active trials include dermatology (4), immunology (1), rare disease (1), and respiratory (1). The portfolio's weighting toward Phase 3 oncology programs suggests a focus on near-term catalysts within that therapeutic area, particularly in solid tumors and non-Hodgkin lymphoma.